Literature DB >> 18274959

Urinary excretion of the main metabolites of 3,4-methylenedioxymethamphetamine (MDMA), including the sulfate and glucuronide of 4-hydroxy-3-methoxymethamphetamine (HMMA), in humans and rats.

N Shima1, M Katagi, H Kamata, K Zaitsu, T Kamata, M Nishikawa, A Miki, H Tsuchihashi, T Sakuma, N Nemoto.   

Abstract

The urinary concentrations of the main metabolites of 3,4-methylenedioxymethamphetamine (MDMA; Ecstasy), specifically 4-hydroxy-3-methoxymethamphetamine sulfate (HMMA-Sul) and 4-hydroxy-3-methoxymethamphetamine glucuronide (HMMA-Glu), have been directly measured in both MDMA users and rats by an established liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS) procedure. The concentrations of these conjugates in urine from MDMA users (n = 25) ranged from 6.5 to 202 microM (from 1.8 to 55.6 microg ml(-1)) for HMMA-Sul and from 1.3 to 87.0 microM (from 0.5 to 32.3 microg ml(-1)) for HMMA-Glu, and the ratio of HMMA-Sul to HMMA-Glu ranged from 1.6 to 9.9 (3.1 +/- 1.8). These results demonstrate that the sulfation is quantitatively more significant than the glucuronidation for HMMA in humans. In rats, in contrast, almost all the conjugated HMMA (>99%) was excreted as the glucuronide. These findings indicate that hydrolysis should be carefully made in urine analysis by gas chromatography (GC) or gas chromatography-mass spectrometry (GC-MS) by using either an acid or an enzyme possessing both sulfatase and beta-glucuronidase activities. It is concluded that a considerable interspecies variation exists in the conjugation of HMMA between humans and rats.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18274959     DOI: 10.1080/00498250701802506

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  7 in total

1.  Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humans.

Authors:  Andrea E Schwaninger; Markus R Meyer; Allan J Barnes; Erin A Kolbrich-Spargo; David A Gorelick; Robert S Goodwin; Marilyn A Huestis; Hans H Maurer
Journal:  Biochem Pharmacol       Date:  2011-09-29       Impact factor: 5.858

2.  Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration.

Authors:  Andrea E Schwaninger; Markus R Meyer; Allan J Barnes; Erin A Kolbrich-Spargo; David A Gorelick; Robert S Goodwin; Marilyn A Huestis; Hans H Maurer
Journal:  Clin Chem       Date:  2011-10-06       Impact factor: 8.327

3.  Development and validation of LC-HRMS and GC-NICI-MS methods for stereoselective determination of MDMA and its phase I and II metabolites in human urine.

Authors:  Andrea E Schwaninger; Markus R Meyer; Marilyn A Huestis; Hans H Maurer
Journal:  J Mass Spectrom       Date:  2011-07       Impact factor: 1.982

4.  Hydrolysis of 3,4-methylenedioxymethamphetamine (MDMA) metabolite conjugates in human, squirrel monkey, and rat plasma.

Authors:  Melanie Mueller; Erin A Kolbrich-Spargo; Frank T Peters; Marilyn A Huestis; George A Ricaurte; Hans H Maurer
Journal:  Anal Bioanal Chem       Date:  2009-01-30       Impact factor: 4.142

5.  Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat.

Authors:  Marta Concheiro; Michael H Baumann; Karl B Scheidweiler; Richard B Rothman; Gina F Marrone; Marilyn A Huestis
Journal:  Drug Metab Dispos       Date:  2013-10-18       Impact factor: 3.922

6.  A validated gas chromatographic-electron impact ionization mass spectrometric method for methamphetamine, methylenedioxymethamphetamine (MDMA), and metabolites in mouse plasma and brain.

Authors:  Karl B Scheidweiler; Allan J Barnes; Marilyn A Huestis
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-11-07       Impact factor: 3.205

7.  Effects of 3-methylmethcathinone on conditioned place preference and anxiety-like behavior: Comparison with methamphetamine.

Authors:  Yang Chen; Libo Zhang; Zengbo Ding; Xianwen Wu; Guibin Wang; Jie Shi
Journal:  Front Mol Neurosci       Date:  2022-07-22       Impact factor: 6.261

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.